Basel, 14 May 2018 Roche to present new phase III data for Hemlibra in people with haemophilia A at the World Federation of Hemophilia 2018 World Congress Data include results from HAVEN 3 study in people with haemophilia A without factor VIII inhibitors and HAVEN 4 study in people with haemophilia A with or without... Read more
Basel, 10 May 2018 Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq® (atezolizumab) and Cotellic® (cobimetinib) did not meet its... Read more
Basel, 10 May 2018 Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq® (atezolizumab) and Cotellic® (cobimetinib) did not meet its... Read more
Defect analysis of components situated in engines and gears Customer Story Audi’s quality assurance department checks various components for faults on a daily basis. The object being investigated is the full bandwidth of vehicle parts – be it interior, exterior, running gear or engine – the objective remains the car as a complete product. To... Read more
Defect analysis of components situated in engines and gears Customer Story Audi’s quality assurance department checks various components for faults on a daily basis. The object being investigated is the full bandwidth of vehicle parts – be it interior, exterior, running gear or engine – the objective remains the car as a complete product. To... Read more
A recent clinical trial, the largest of its kind examining the effect of oral steroids on patients with immunoglobulin A (IgA) nephropathy, has found a greater than anticipated increase in the risk of serious adverse events. IgA nephropathy is an immune disease, where the antibody immunoglobulin A causes damage to the kidney. Almost one-third of... Read more
See Change™ with the new AQS3pro System for protein characterization from RedShiftBio. One highly automated system, five key measurements: Aggregation, Quantification, Stability, Structure and Similarity April 30, 2018 07:59 AM Pacific Daylight Time BOSTON–(BUSINESS WIRE)–At PEGS 2018 (April 30th – May 4th, Boston, MA) RedShift™ BioAnalytics, Inc. (RedShiftBio™) will unveil the AQS3™pro, a new protein... Read more
April 30, 2018 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, launched Hound and Bouncer today at the PEGS conference in Boston. The QC duo are the ultimate tools for getting biopharmaceutical manufacturers to particle-free biologics and trouble-free drug delivery devices... Read more
LOS ANGELES, April 25, 2018 (GLOBE NEWSWIRE) — Top-Down Analytics (TDA), a Los Angeles- based market research and management consulting firm has announced a new market report entitled Metabolomics 2018: Charged with Massive Potential. Over the past five years, the market for metabolomics research has increased dramatically, with LC/MS and NMR leading the charge in... Read more
Germantown, Maryland, and Hilden, Germany, April 20, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory approval of PartoSure®, which is a novel test for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor. The pre-market approval of PartoSure by the U.S. Food and... Read more